On March, 11 GTx, Inc. (GTXI) Analysts See $-0.22 EPS

GTx, Inc. (NASDAQ:GTXI) Corporate Logo

On March, 11 WallStreet anticipated GTx, Inc. (NASDAQ:GTXI)’s earnings release, Faxor reports. Analysts forecast $-0.22 EPS. That’s $0.21 up or 48.84 % from 2018’s earnings of $-0.43. -43.59 % EPS growth is what analysts predict. $-0.39 EPS was revealed for previous quarter. The stock decreased 2.49% or $0.0246 during the last trading session, touching $0.9634.GTx, Inc. has volume of 75,503 shares. Since February 12, 2018 GTXI has declined 90.30% and is downtrending. GTXI underperformed the S&P 500 by 90.30%.

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions.The company has $23.17 million market cap. It focuses on the development of selective androgen receptor modulators for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC).Currently it has negative earnings. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI.

For more GTx, Inc. (NASDAQ:GTXI) news announced briefly go to: Seekingalpha.com, Businesswire.com, Marketwatch.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “GTx’s enobosarm flunks late-stage study in women with SUI; shares down 91% premarket – Seeking Alpha” announced on September 21, 2018, “GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at a Podium Presentation at 2018 AUA Annual Meeting – Business Wire” on April 16, 2018, “Dow posts back-to-back records, but tech woes weigh on broader market – MarketWatch” with a publish date: September 21, 2018, “Gtx up 51% premarket – Seeking Alpha” and the last “New Research Coverage Highlights Adesto Technologies, Pain Therapeutics, US Global Investors, GTx, Columbus McKinnon, and Baytex Energy — Consolidated Revenues, Company Growth, and Expectations for 2018 – GlobeNewswire” with publication date: October 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.